Request Demo
Recent blog posts
Latest Hotspot
8 min read
Glioblastoma Indication Strategy Report 2026: EGFR, VEGF, Trials and Deal Outlook
20 July 2026
A 2026 glioblastoma strategy report covering disease burden, EGFR and VEGF biology, clinical competition, recent deals and portfolio positioning.
Latest Hotspot
8 min read
IDH-Mutant Glioma Indication Strategy Report 2026: IDH1/2, Trials and Deal Outlook
20 July 2026
A 2026 IDH-mutant glioma strategy report covering molecular biology, epidemiology evidence, clinical competition, transaction signals and portfolio positioning.
Latest Hotspot
8 min read
Chronic Myeloid Leukemia Indication Strategy Report 2026: BCR-ABL, Resistance and Trial Outlook
20 July 2026
A 2026 CML strategy report covering BCR-ABL biology, resistance, treatment-free remission, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Acute Lymphoblastic Leukemia Indication Strategy Report 2026: CD19, CD22, Trials and Deal Outlook
20 July 2026
A 2026 ALL strategy report covering disease burden, CD19 and CD22 biology, clinical competition, recent transactions and portfolio positioning.
Latest Hotspot
8 min read
Urothelial Carcinoma Indication Strategy Report 2026: Nectin-4, FGFR3, Trials and Deal Outlook
20 July 2026
A 2026 urothelial carcinoma strategy report covering epidemiology, Nectin-4 and FGFR3 biology, clinical competition, deal signals and portfolio positioning.
Latest Hotspot
8 min read
Melanoma Indication Strategy Report 2026: BRAF, LAG-3, Trials and Deal Outlook
20 July 2026
A 2026 melanoma strategy report covering global burden, BRAF and LAG-3 biology, clinical competition, recent transactions and portfolio positioning.
Latest Hotspot
8 min read
Acute Myeloid Leukemia Indication Strategy Report 2026: FLT3, Menin, Trials and Deal Outlook
20 July 2026
A 2026 AML strategy report covering disease burden, FLT3 and menin biology, clinical competition, recent transactions and portfolio positioning.
Latest Hotspot
8 min read
Diffuse Large B-Cell Lymphoma Indication Strategy Report 2026: CD19, CD20, Trials and Deal Outlook
20 July 2026
A 2026 DLBCL strategy report covering disease burden, CD19 and CD20 biology, clinical competition, recent transactions and portfolio positioning.
Latest Hotspot
8 min read
HK inno.N Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
HK inno.N 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Daewoong Pharmaceutical Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Daewoong Pharmaceutical 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
GC Biopharma Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
GC Biopharma 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.
Latest Hotspot
8 min read
Yuhan Corporation Company BD Opportunity Scan Report 2026: Pipeline, Deals, Partnering Shortlist, and Outreach Priorities
20 July 2026
Yuhan Corporation 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.